clinical trial · NCT05030441
Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
Clonal Cytopenia of Undetermined SignificanceIvosidenib
brief summary
This is an open-label, multicenter study exploring the efficacy of ivosidenib in patients with clonal cytopenia of undetermined significance (CCUS) with mutations in IDH1. The purpose is to establish proof of principle that ivosidenib is well-tolerated and potentially efficacious in improving blood count abnormalities in these patients. The study will also be offered in a decentralized, remote structure to patients.
started
Apr 1, 2022
primary completion
Jan 31, 2030
completion
Jan 31, 2030
last updated
Aug 14, 2025
official title
A Pilot Study of Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol